Humana Inc. (NYSE:HUM) Shares Acquired by Paradigm Asset Management Co. LLC

Paradigm Asset Management Co. LLC increased its position in shares of Humana Inc. (NYSE:HUM) by 766.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,600 shares of the insurance provider’s stock after buying an additional 2,300 shares during the quarter. Paradigm Asset Management Co. LLC’s holdings in Humana were worth $660,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. AMF Tjanstepension AB lifted its stake in shares of Humana by 166.8% in the 3rd quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock valued at $12,686,000 after purchasing an additional 25,041 shares during the last quarter. Sequoia Financial Advisors LLC lifted its position in Humana by 3.2% in the third quarter. Sequoia Financial Advisors LLC now owns 2,408 shares of the insurance provider’s stock valued at $763,000 after buying an additional 74 shares during the last quarter. Eastern Bank purchased a new position in Humana during the third quarter worth about $90,000. Lecap Asset Management Ltd. purchased a new position in Humana during the third quarter worth about $520,000. Finally, IFM Investors Pty Ltd raised its stake in shares of Humana by 0.5% in the 3rd quarter. IFM Investors Pty Ltd now owns 25,370 shares of the insurance provider’s stock valued at $8,036,000 after acquiring an additional 131 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Performance

Shares of HUM stock opened at $255.77 on Friday. The company has a market cap of $30.80 billion, a P/E ratio of 25.71, a PEG ratio of 2.00 and a beta of 0.56. The firm has a fifty day moving average price of $269.41 and a 200 day moving average price of $290.45. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.38%. Humana’s dividend payout ratio is currently 35.58%.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.32% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

HUM has been the subject of a number of research analyst reports. Piper Sandler increased their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. JPMorgan Chase & Co. lowered their price target on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday. Royal Bank of Canada reiterated an “outperform” rating and issued a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. Morgan Stanley decreased their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Finally, TD Cowen lifted their target price on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Nineteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.